Fortis Group Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,105
Closed -$270K – 622
2026
Q2
$270K Buy
1,105
+5
+0.5% +$1.08K 0.04% 231
2026
Q1
$229K Hold
1,100
– – 0.04% 265
2025
Q4
$203K Buy
+1,100
New +$154K 0.03% 271

Other funds holding AXSM

Fortis Group Advisors's AXSM Position: Q3 2026 in Review

Fortis Group Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 1,105 shares — an estimated $270K sold.

Fortis Group Advisors first reported a position in AXSM in Q4 2025 and held it in 3 quarters. The position peaked at $270K in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Fortis Group Advisors reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Fortis Group Advisors sold 1,105 Axsome Therapeutics shares in Q3 2026, an estimated $270K.
  • Fortis Group Advisors first reported a position in Axsome Therapeutics in Q4 2025 and held it in 3 quarters.
  • Fortis Group Advisors's Axsome Therapeutics position peaked at $270K in Q2 2026.
  • 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Fortis Group Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.